Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
The Utilization of Low Dose Naltrexone for Chronic Pain.
CNS Drugs. 2023 Aug;37(8):663-670. doi: 10.1007/s40263-023-01018-3. Epub 2023 Jul 28.
CNS Drugs. 2023.
PMID: 37505425
Naltrexone is a mu-opioid receptor antagonist with a long half-life compared with naloxone. Both of these drugs, along with others, were developed with the intention of reversing the effects of opioid abuse or toxicity. Evidence has also shown that nal …
Naltrexone is a mu-opioid receptor antagonist with a long half-life compared with naloxone. Both of these drugs, along with ot …
Identification of a novel opioid, N-piperidinyl etonitazene (etonitazepipne), in patients with suspected opioid overdose.
Calello DP, Aldy K, Jefri M, Nguyen TT, Krotulski A, Logan B, Brent J, Wax P, Walton S, Manini AF; ToxIC Fentalog Study Group.
Calello DP, et al.
Clin Toxicol (Phila). 2022 Sep;60(9):1067-1069. doi: 10.1080/15563650.2022.2084406. Epub 2022 Jun 16.
Clin Toxicol (Phila). 2022.
PMID: 35708103
Free PMC article.
Data collected included reported substance use, clinical course, naloxone dose and response, outcome, and analytes detected in biological samples. ...Two of three received subsequent doses for recurrence of opioid toxicity (0.4-0.6 mg IV). One p …
Data collected included reported substance use, clinical course, naloxone dose and response, outcome, and analytes detected in …
Item in Clipboard
Cite
Cite